Synaffix’s Licensing Agreement with Amgen

Goodwin Procter advised Synaffix on the deal. Synaffix announced a licensing agreement with Amgen to develop next generation of antibody-drug conjugates (ADCs) using Synaffix technology. Under the...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here